Skip to main content

MacroGenics

2022 Breast Cancer Guide to Patient Support Services

MacroGenics Patient Support

844-633-6469

MacroGenics offers the Margenza Patient Support program to assist patients and their healthcare providers with access to Margenza (Table). Healthcare providers and prescribers can call 844-MED-MGNX (844-633-6469) to speak with a case manager who can assist with ordering information, reimbursement support, information on the Patient Assistance Program and Copay Assistance Program, and benefit investigations.

Margenza Patient Support

By enrolling in Margenza Patient Support, patients may receive various forms of support and information to help access Margenza, including insurance verification/prior authorization/appeals support, copay assistance, and other financial support.

Patient Support Program and Copay Assistance Program

Patients may be eligible for the Copay Assistance Program if they:

  • Have commercial insurance that covers the prescribed medicine, but not the full cost of the medicine
  • Are not participating in any state or federal healthcare program including Medicaid, Medicare, Medicare Part D, Medigap, Veterans Affairs, CHAMPUS, Department of Defense, TRICARE, or any state patient or pharmaceutical assistance program
  • Are aged ≥18 years
  • Are residents of the United States or Puerto Rico
  • Have a prescription for Margenza for an FDA-approved indication.

To enroll your patient, complete the application and fax to 844-256-5226.

Patient Support Program and Patient Assistance Program

Margenza Patient Support offers a Patient Assistance Program to help qualifying patients obtain Margenza at no cost. Patients may be eligible for the Patient Assistance Program if they:

  • Are aged ≥18 years
  • Have a prescription for Margenza for an FDA-approved indication
  • Receive treatment in an outpatient setting
  • Will receive treatment within 180 days of application approval, if granted
  • Their annual household income is at or below 400% of the federal poverty guidelines
  • Are permanent, legal residents of the United States, Puerto Rico, or the US Virgin Islands
  • Have no insurance, or insurance that does not cover Margenza, and are not eligible for other public health insurance programs other than Medicare Part D.

To enroll your patient, complete the application and fax to 844-256-5226.

TABLE MacroGenics Breast Cancer Drug

Drug
Indication
Patient support programs
Drug
Margenza (margetuximab-cmkb)
Indication
In combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 regimens, at least 1 of which was for metastatic disease
Patient support programs